• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Strive (ASST) Rebounds Sharply, Is The Remaining Upside Already Priced In?

    Simply Wall St·09/24/2026 18:35:51
    Listen to the news

    Strive (ASST) has drawn fresh attention after recent trading left the shares with a year-to-date gain of 67.6%, alongside a decline of 51.8% over the past year.

    Recent trading in Strive reflects sharp swings in sentiment, with a 30-day share price return of 46.93% and a 90-day share price gain of 154.30%. However, the 1-year total shareholder return is still down 51.84%, suggesting momentum has picked up only in the short term.

    Scan fresh momentum stories like Strive alongside other fast-moving opportunities in our curated list of 30 high quality undervalued stocks.

    Strive’s share price has raced ahead of most analyst targets, with the stock now only about 15% below the consensus estimate. Is that gap signaling remaining upside, or is the market already pricing in too much?

    Preferred Multiple of 3.8x Price-to-Book: Is it justified?

    The recent surge in Strive's share price lands investors in the middle of a valuation debate, because the stock trades on a P/B ratio of 3.8x while long term total returns over 1 and 3 years are still in negative territory.

    P/B compares the market value of the equity to its accounting book value. This can be a useful gauge for asset-heavy or financial groups such as an investment manager. In Strive's case, the business is currently loss making, with a reported net loss of $975.456m, so earnings-based metrics such as P/E do not offer much clarity. That makes the 3.8x P/B one of the cleaner signals available.

    On that measure, the stock screens as "good value" against its own peer set at 6x P/B. This implies the market is assigning a lower valuation than similar companies with comparable balance sheets. The same 3.8x multiple is described as expensive relative to the broader US Medical Equipment industry average of 2.7x, so the gap cuts both ways and leaves the interpretation highly dependent on which comparator group an investor views as more relevant.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 3.8x (ABOUT RIGHT)

    Still, Strive’s steep 1 year and 3 year total return declines, alongside a net loss of US$975.456m, could quickly challenge any renewed optimism.

    Find out about the key risks to this Strive narrative.

    Next Steps

    Strive splits opinion right now, with sharp recent gains sitting against heavy past losses and a sizeable net loss on the books. If you want to judge that tension for yourself and see how the trade off between potential upside and the known financial and business risks stacks up in the data, take a closer look at the 1 key reward and 3 important warning signs.

    Looking for more Strive style investment ideas?

    Do not stop your research with Strive. Broaden your watchlist with fresh ideas filtered by clear fundamentals so you are not chasing every headline swing.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.